Op. Dr. İskender Alkın Solmaz is an experienced ophthalmologist specialized in ophthalmic plastic and reconstructive surgery. He began his education at İstiklal Makzume Anatolian High School and graduated from English Medical Program of Marmara University in 2003. He completed his residency training in ophthalmology at Şişli Etfal Training and Research Hospital and Okmeydanı Training and Research Hospital, becoming a specialist in 2009.

Throughout his career, Dr. Solmaz has served in various regions of Turkey. After serving as a military doctor in Adana, he fulfilled his mandatory state service in Antakya/Hatay. In 2011, he returned to Istanbul and worked for almost 8 years in Etiler branch of Dünya Göz Hospital, focusing on ocular plastic and facial plastic surgery. In 2019, he started his private practice, Turkey’s first aesthetic clinic focused on eye and face.

Dr. Solmaz has performed over 25,000 surgical procedures in ophthalmic plastic surgery, including operations on eyelids, eyebrows, and the tear system, with both aesthetic and reconstructive goals. He is also an expert on treating periocular structures and facial tumors, tear duct blockages, Graves’ orbitopathy, and managing conditions related to eye loss and prosthetic eye applications.

Dr. Solmaz closely follows scientific advancements and participates in numerous national and international conferences. He is frequently invited as a speaker, especially on topics related to the eyes and periocular areas. He is an active member of Turkish Ophthalmology Society (TOD), Turkish Facial Plastic Surgery Society (YPCD), and European Association of Facial Plastic Surgery (EAFPS). 

As an enterpreneur, he is one of the co-founders of TelomEye Pharmaceuticals in Toronto, Canada, which he started as the inventor of the concept with a group of colleagues in 2021. The company focuses on preventing and treating age-related diseases commonly encountered in ophthalmology. In its first funding round, the company received an investment of approximately $1 million USD with a valuation of $10 million USD. Clinical trials are going on with promising results.

Importantly than all Dr. Solmaz is father of a 16-year-old son and a 13-year-old daughter.